Should I Buy GPCR? GPCR 2026 Analysis

Should You Buy Structure Therapeutics Inc (GPCR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

74.920

1 Day change

2.34%

52 Week Range

94.900

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now: Price is sitting essentially on first support (~81.28) after a pullback, while the broader fundamental/news backdrop (oral GLP-1/obesity + M&A narrative + fresh capital) remains strongly supportive.
Trade-off for an impatient buyer: Near-term technical momentum is still soft (bearish MACD), so you may see additional downside noise toward ~77.66 (S2), but the current location near support makes the risk/reward acceptable for immediate entry.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is -1.662 and negatively expanding → downside momentum still present.
RSI: RSI(6) 30.85 → near oversold/washed-out territory (often consistent with support testing rather than strength).
Moving averages: SMA_5 > SMA_20 > SMA_200 → bigger-picture structure remains bullish despite the recent pullback.
Key levels:
- Support: S1 81.276 (price ~81.3–81.7 is right on it), then S2 77.658.
- Resistance: Pivot 87.132, then R1 92.988.
Pattern-based forward odds (provided): higher chance of weakness over 1 day / 1 week, but positive bias over 1 month (+12.21%) → fits a “buy near support for a 1–4 week rebound” profile.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put/Call ratios are very low (OI 0.37; Volume 0.19) → options market skew is bullish (more call interest than puts).
Volatility: 30D IV ~81% vs historical vol ~69% → options are pricing elevated moves; sentiment is bullish but expects large swings.
Flow/Activity: Today’s option volume 320 vs 5D/10D averages (1660/1359) suggests lighter-than-recent activity, i.e., no obvious “panic hedge” today.
Open interest: Calls OI (10,448) materially exceeds puts OI (3,893) → reinforces bullish tilt.

Technical Summary

Sell

Buy

Positive Catalysts

- M&A/strategic interest narrative: Company highlighted as a potential acquisition target; M&A expert cited upside to valuation (~$9B vs ~$6.3B referenced).
- Strategic validation: Genentech entered a $100M deal tied to a GLP-1 weight-loss drug, supporting platform credibility.
- Balance sheet catalyst: Completed a $650M public offering to fund R&D/expansion (extends runway for clinical execution).
- Product story: Street continues to frame aleniglipron as a highly competitive oral GLP-1 opportunity with scarcity value.

Neutral/Negative Catalysts

- Short-term price/technical pressure: Regular session was -2.91% and MACD is still deteriorating → momentum traders may keep leaning on the stock near-term.
- Support risk: If ~81.3 (S1) fails, next technical magnet is ~77.7 (S2).
- Pre-revenue profile: Financials show no meaningful revenue yet, so valuation is mostly expectation-driven and news/clinical-flow sensitive.
- Near-term statistical bias (provided): pattern analysis implies -4.79% over the next week risk window despite a bullish 1-month outlook.

Financial Performance

Latest quarter provided: 2025/Q3
Revenue: 0 (no change YoY) → still effectively pre-commercial.
Profitability trend: Net income improved to -65.7M (loss narrowed ~93.4% YoY) → meaningful cost/other-income swing, but still loss-making.
EPS: -0.37, improved ~85% YoY → trending better, but not yet near profitability.
Runway/financing: The $650M offering (news) is a tangible positive for funding upcoming clinical/R&D needs.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Clear uptrend in Street stance and targets (Dec 2025 → Jan 2026): Multiple firms raised price targets sharply following Phase 2/2b updates and positioning vs Lilly’s oral GLP-1.
Recent highlights:
- Goldman Sachs (2026-01-19): upgraded to Buy, PT $102 (scarcity value; Phase 2 de-risking).
- JPMorgan (2026-01-22): Overweight, PT raised to $105 (pipeline adds “another leg,” amylin program noted).
- Morgan Stanley (2025-12-08): Overweight, PT $120 (competitive efficacy; models 2028 U.S. launch).
- Citi / Stifel / Clear Street / H.C. Wainwright: reiterated Buy/positive, PTs mostly $90–$100+ (post-data).
Wall Street pros: strong efficacy/tolerability narrative for oral obesity drug, scarcity value, partnership/M&A optionality.
Wall Street cons: timing-to-market is still forward (development risk remains), and the stock can react sharply to any trial/regulatory or competitive updates.

13 Analyst Rating

Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 104 USD with a low forecast of 65 USD and a high forecast of 130 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 73.210

Low

Averages

104

High

130

Current: 73.210

Low

Averages

104

High

130

JPMorgan

NULL

Overweight

maintain

$65 -> $105

AI Analysis

2026-01-22

Reason

JPMorgan

Price Target

$65 -> $105

AI Analysis

2026-01-22

maintain

NULL

Overweight

Reason

JPMorgan raised the firm's price target on Structure Therapeutics to $105 from $65 and keeps an Overweight rating on the shares. The firm sees the upcoming data of the company's oral small molecule amylin, ACCG-2671, in the second half of 2026 adding " another leg to the story." Structure may have a "differentiated offering" in addition to aleniglipron, which is on track to be the second oral small molecule GLP-1 to market, the analyst tells investors in a research note.

Goldman Sachs

NULL

Buy

upgrade

$102

2026-01-19

Reason

Goldman Sachs

Price Target

$102

2026-01-19

upgrade

NULL

Buy

Reason

Goldman Sachs moved Structure Therapeutics (GPCR) to Buy rating and $102 price target from Early Stage Biotech. The company's oral small molecule GLP-1 aleniglipron has shown to be competitive against Eli Lilly's (LLY) orforglipron, the analyst tells investors in a research note. The firm views Structure's Phase 2 data as "de-risking" and sees scarcity value for the shares. Structure has a an oral small molecule that could be second to market only behind Lilly's orforglipron, contends Goldman.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GPCR

Unlock Now

GPCR Should I Buy

GPCR Should I Buy

Should You Buy Structure Therapeutics Inc (GPCR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch